Compare AZTR & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZTR | OMH |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.2M |
| IPO Year | 2023 | 2022 |
| Metric | AZTR | OMH |
|---|---|---|
| Price | $0.14 | $0.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 901.1K | ★ 33.2M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.40 |
| Revenue Next Year | N/A | $23.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.09 |
| 52 Week High | $1.40 | $2.19 |
| Indicator | AZTR | OMH |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 36.46 |
| Support Level | $0.12 | N/A |
| Resistance Level | $0.15 | $1.09 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 49.30 | 0.18 |
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.